CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow -2.0% ·
net new positions +5.6%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +10 | 52.52M | $4.57B | +17 | −8 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | n/a |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | n/a |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | n/a |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | n/a | n/a |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | n/a | −1 |
| Q2 2024 | 13 | n/a | 13.78M | $447.82M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 12.53M | n/a | $919.76M | 0.0% | n/c | 1 | SEC ↗ ×19 |
| 2 | The Vanguard Group ✦ (passive) | 9.68M | n/a | $710.56M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 6.27M | +2.0% | $459.95M | 0.6% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 2.97M | -12.8% | $217.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.92M | -15.2% | $141.14M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Fidelity (FMR) ✦ | 1.36M | n/a | $99.60M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Norges Bank ✦ (passive) | 981.58K | +15.6% | $72.05M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 788.81K | -47.1% | $57.90M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 673.14K | -3.9% | $49.41M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 10 | Citadel Advisors ✦ | 446.00K | +1478.0% | $32.74M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 260.56K | -7.6% | $19.13M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 232.99K | -7.9% | $17.10M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 13 | T. Rowe Price ✦ | 147.09K | +126.7% | $10.80M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Adage Capital Partners ✦ | 96.17K | New | $7.06M | 0.0% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 60.84K | -66.2% | $4.47M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Marshall Wace ✦ | 46.20K | +795.4% | $3.39M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Wellington Management ✦ | 33.53K | -5.6% | $2.46M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 18 | Gotham Asset Management ✦ | 17.31K | -0.6% | $1.27M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $7.06M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 347 holders, 79.01M shares, $2.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 6.65K sh · $761,717
Director · 3.05K sh · $351,476
Director · 300 sh · $34,889
Officer · 15.84K sh · $1.84M
Officer · 4.74K sh · $552,869
Officer · 8.74K sh · $1.02M
Officer · 4.45K sh · $514,389
Officer · 5.15K sh · $600,063
Officer · 1.10K sh · $125,973
Officer · 2.09K sh · $241,412
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology